usdaed

Eli Lilly, to its credit, was quick off the mark with Mounjaro and Zepbound, which have proven remarkably effective at… well, reducing appetite. They now account for a rather alarming 56% of the company’s revenue. Which is, statistically speaking, a lot. (Imagine building an entire financial empire on the premise that people want to eat less. It’s a bold strategy, Cotton, let’s see if it pays off.) The market, however, seems to believe this is not merely a temporary trend, but a permanent reshaping of the human condition. Hence the rather enthusiastic price-to-earnings ratio of 44 and a dividend yield that wouldn’t trouble a particularly frugal ant. It’s priced for perfection, which, as any seasoned trader knows, is a dangerous place to be. (Perfection, much like a perfectly brewed cup of tea, is an elusive and ultimately unattainable goal. Striving for it only leads to disappointment and lukewarm beverages.)

Yet, the market, that fickle mistress, has recently exhibited a touch of the vapors regarding Meta’s expenditures. Investors, it appears, are beginning to suspect that throwing vast sums at innovation doesn’t necessarily guarantee a proportionate return. A rather novel concept, though one suspects the truly astute have always known it. The worry, as it were, is that the potential revenue from this digital alchemy may not quite match the expense of the ingredients.

AWS demonstrated robust growth in the fourth quarter of 2025, reporting a 24% year-over-year revenue increase. While Amazon possesses internal hardware design capabilities, the complexity and capital intensity of developing a complete AI hardware ecosystem necessitate reliance on external providers. Nvidia currently occupies a dominant position in this landscape.

The S&P 500 is hitting highs, sure. But that doesn’t mean this AI stuff is any different. It just means people are easily distracted. They see a shiny new toy and suddenly forget all the basic principles of investing. It’s like they’ve never seen a pump-and-dump before. Honestly, it’s insulting.

To speak of Taiwan Semiconductor Manufacturing (TSM 4.23%) is to speak of a near-total dominion. It is a position achieved not through superior vision, but through the relentless, unforgiving demands of a process – the fabrication of logic chips – that few others possess the capital, the expertise, or, frankly, the will to master. The shrinking of nodes, the pursuit of density… these are not merely technical challenges, but acts of attrition, slowly eliminating competitors, concentrating power into fewer and fewer hands. The foundries, those vast, humming cathedrals of silicon, require near-constant utilization to justify their existence – a precarious balance, demanding a constant flow of orders, a dependence that TSMC has skillfully cultivated.

exist. Consistently. Year after year. It’s a pharmaceutical leviathan, a medical device behemoth, and a consumer goods juggernaut all rolled into one. Frankly, it’s terrifying. They’re in everything, touching every aspect of the healthcare system. Patent cliffs? Drug price negotiations? They shrug it off like a minor inconvenience. They’ll hit $100 billion in revenue this year, they say. A hundred BILLION. The sheer audacity of it all. And their balance sheet? Stronger than the U.S. government’s. That should tell you something. Something deeply unsettling. They’re launching new products, robotic surgery systems, clinical trials… it’s a relentless cycle of innovation and expansion. A Dividend King, they call themselves. Fifty consecutive years of dividend hikes. FIFTY. It’s a monument to corporate inertia, a testament to their ability to squeeze profits out of every conceivable angle. It’s not pretty. It’s not glamorous. But it’s effective. And in this twisted game we call finance, effectiveness is all that matters.

This momentary rise, you see, was not born of robust trade winds or shrewd navigation, but rather the arrival of Elliott Management, an activist hedge fund with a near-10% stake. They presented a… shall we say, ‘assessment’ – a document filled with promises of improvement, as if one could simply order a cruise line to perform better. It was a presentation, one suspects, composed of more hope than actual analysis, like a map drawn by a seagull.

A recent study – a surprisingly rigorous undertaking, given the general state of things – by Hartford Funds, in collaboration with Ned Davis Research, suggests that dividend-paying stocks have, over the long haul (1973-2024, to be precise), outperformed non-dividend payers by a significant margin: 9.2% versus 4.31% annualized. This, of course, doesn’t prove anything, merely suggests a correlation. It could, for instance, be that successful companies are simply better at both generating profits and remembering to send checks. A thought, isn’t it?

Recursion, a healthcare enterprise dabbling in the algorithmic arts, promises a revolution in drug discovery. It’s a charming notion, though one must always suspect that promises, like perfumes, lose their potency upon closer inspection. The company’s operating system, a digital oracle of sorts, attempts to divine which clinical compounds might survive the gauntlet of trials and regulations. A noble pursuit, to be sure, but one that has, thus far, yielded little more than elegantly charted failures.

The streaming giant, having abandoned its grand, if improbable, pursuit of Warner Bros. Discovery – a union as ill-fated as a hummingbird trying to navigate a hurricane – has turned its attention to something smaller, quieter, yet perhaps more unsettling. A sliver of the $2.8 billion severance, the price of a broken promise, has been redirected towards InterPositive, an artificial intelligence company founded by none other than Ben Affleck. The name itself, a relic of old filmmaking techniques, whispers of a desire to preserve something lost, to bottle the ephemeral magic of celluloid in the cold logic of code. It was a secret, of course, kept hidden like a forgotten reel in a dusty archive, until Thursday, when the inevitable revelation arrived.